GLP1R and obesity disorder: Another unimolecular once-weekly dual GLP-1R/GCGR agonist is efinopegdutide (MK-6024), which was able to prove significant reductions in body weight compared to placebo, but no reductions of the HbA1c levels, when investigated in people with obesity and T2DM.